Biblio Discovery — Demo Discovery Service

23 hasil untuk "A. Mosca"

Menampilkan 1–20 · 0,55 detik · RSS

  1. Artikel Jurnal

    Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL Study (Diabete, Ipertensione, Albuminuria, Lercanidipina)

    M. Dalla Vestra; G. Pozza; A. Mosca dkk.

    Кардиоваскулярная терапия и профилактика, Vol. 9 No. 7 · 1970 · Rusia · DOAJ Scopus

    Aim. Microalbuminuria (MAU) and hypertension (AH) are risk factors (RFs) for diabetic nephropathy in patients with Type 2 diabetes mellitus (DM-2). Recent data suggest that blockade of the renin-angiotensin system (RAS) slows the progression of diabetic nephropathy. In contrast, the results on the…

  2. Artikel Jurnal

    Update on vaccination of preterm infants: a systematic review about safety and efficacy/effectiveness. Proposal for a position statement by Italian Society of Pediatric Allergology and Immunology jointly with the Italian Society of Neonatology.

    Elena Chiappini; Chiara Petrolini; Elena Sandini dkk.

    Expert Review of Vaccines, Vol. 18 No. 5 · 2019 · Inggris · DOAJ Scopus

    Introduction: Preterm infants (PIs) are at increased risk of vaccine-preventable diseases (VPDs). However, delayed vaccination start and low vaccine coverage are still reported. Areas covered: This systematic review includes 37 articles on preterm vaccination published in 2008–2018 in PubMed. Both…

  3. Artikel Jurnal

    PKM2 modulation regulates leukemia cell survival

    Nikolina Vrdoljak; Ekaterina N. Parfenova; Alessia Roma dkk.

    Cancer & Metabolism, Vol. 14 No. 1 · 2026 · Inggris · DOAJ

    Abstract Acute myeloid leukemia (AML) cells exhibit aberrant metabolism defined by a shift away from oxidative phosphorylation and towards anaerobic glycolysis, favouring cell growth. Glycolytic enzymes are altered for this change to occur, including pyruvate kinase (PK), where the tetrameric and…

  4. Artikel Jurnal

    P115 | CUTANEOUS INVOLVEMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA: REAL-WORLD OUTCOMES WITH VENETOCLAX-OBINUTUZUMAB AT FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS.

    I. Innocenti; A. Tomasso *; L. Stirparo * dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Introduction: Cutaneous manifestations are rare in patients with chronic lymphocytic leukaemia (CLL) and may result from either direct leukemic infiltration or the general predisposition of CLL patients to secondary conditions. Leukaemia cutis (LC), caused by skin infiltration of leukemic cells, is…

  5. Artikel Jurnal

    P123 | IBRUTINIB AND VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OUTSIDE CLINICAL TRIALS: A SINGLE-CENTER REAL-WORLD EXPERIENCE

    A. Tomasso; I. Innocenti *; L. Stirparo * dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Introduction: The combination of ibrutinib, a Bruton's tyrosine kinase inhibitor, and venetoclax, a BCL-2 inhibitor, has shown synergistic efficacy in chronic lymphocytic leukemia (CLL). Pivotal trials like CAPTIVATE and GLOW report high rates of complete remission (CR) and undetectable minimal…

  6. Artikel Jurnal

    P106 | ONCOGERIATRIC ASSESSMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS OVER 65 YEARS IN TARGET ERA. A MONOCENTRIC PILOT STUDY AT FONDAZIONE POLICLINICO A. GEMELLI, ROME

    I. Innocenti; L. Stirparo; A. Tomasso dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Introduction: Chronic lymphocytic leukemia (CLL) primarily affects elderly adults. While targeted agents such as BTKi and BCL-2 inhibitors have improved outcomes, their use in elderly patients raises concerns regarding tolerance and toxicity, and there is still no established method for defining…

  7. Artikel Jurnal

    P120 | CHRONIC LYMPHOCYTIC LEUKEMIA AND RENAL CELL CARCINOMA: A CASE SERIES OF TWELVE PATIENTS

    T. Quaranta; F. Guglielmi; A. Tomasso dkk.

    Haematologica, Vol. 110 No. s1 · 2025 · Inggris · DOAJ Scopus

    Background: Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults, with a median age at diagnosis of 72 years. CLL patients (pts) have an increased risk of second malignancies due to multiple synergistic factors: genetic, environmental, treatment-induced and immunomodulatory…